Attovia Therapeutics

Attovia Therapeutics stock approaches October 8 data presentations after a USD 17.17 last price on Nasdaq. Six analysts carry a Moderate Buy consensus and a USD 42.20 average target.

SAN CARLOS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (

Attovia Therapeutics (ATTO) has been drawing attention after a recent pullback, with the share price closing at US$21.30. The move comes as investors weigh performance in immune-mediated disease programs and current valuation. Short term sentiment around

SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (

--Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that company management will participate in the following upcoming inves

SAN CARLOS, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (

Attovia Therapeutics, a privately-held, clinical-stage biopharma company developing treatments for immune-mediated diseases with high unmet patient need, announced the closing of a $90 million Series C funding. Deep Track Capital led this funding round wi